Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 6 Researches
7.2
USERS' SCORE
Good
Based on 14 Reviews
8.2
Supplement Facts
Serving Size: 1 Tablet
Amount Per Serving
%DV
Folate (800 mcg L-methylfolate) (as L-methylfolate as Metafolin®)
1,333 mcg DFE
333%
Top Medical Research Studies
7
We aimed to understand how folate receptor alpha autoantibodies (FRAAs) relate to symptoms in children diagnosed with Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS). We analyzed serum samples from 47 children, aged 6 to 18, who carried these diagnoses.
Our results showed that a significant number of these children—about 63.8%—had binding or blocking FRAAs. Additionally, certain symptoms, like severe tics, linked with higher FRAA binding titers. Notably, we observed that kids with autism spectrum disorder (ASD) had lower binding titers of FRAAs.
A remarkable case highlighted how treatment with leucovorin, a form of folate, resulted in symptom improvements in a child with PANS/PANDAS who tested positive for FRAAs. These findings suggest that abnormalities in folate metabolism could play a role in the symptomatology of PANS/PANDAS, presenting the potential for folate-based therapies to be a viable treatment option.
Overall, this study sheds light on the connection between folate-related factors and pediatric neuropsychiatric disorders, calling for further research into leucovorin as a targeted treatment.
Our results showed that a significant number of these children—about 63.8%—had binding or blocking FRAAs. Additionally, certain symptoms, like severe tics, linked with higher FRAA binding titers. Notably, we observed that kids with autism spectrum disorder (ASD) had lower binding titers of FRAAs.
A remarkable case highlighted how treatment with leucovorin, a form of folate, resulted in symptom improvements in a child with PANS/PANDAS who tested positive for FRAAs. These findings suggest that abnormalities in folate metabolism could play a role in the symptomatology of PANS/PANDAS, presenting the potential for folate-based therapies to be a viable treatment option.
Overall, this study sheds light on the connection between folate-related factors and pediatric neuropsychiatric disorders, calling for further research into leucovorin as a targeted treatment.
Read More
9
Folate's Role in Rheumatoid Arthritis
We explored the potential of folate-modified ginger-derived extracellular vesicles (FA-GDEVs) in treating rheumatoid arthritis (RA). This innovative approach aims to tackle the ongoing inflammation and joint damage that characterizes this autoimmune disorder. By using folate, which selectively targets specific receptors on inflammatory cells, we specifically directed these vesicles to M1 macrophages in inflamed joints.
Our findings show that FA-GDEVs can help encourage a shift from harmful M1 macrophages to a healing M2 phenotype. This shift is significant because M2 macrophages play a role in tissue repair and reducing inflammation. We also investigated how these vesicles activate the PI3K-AKT pathway, a crucial cellular pathway involved in regulating immune response.
In our in vivo studies, we noted that these folate-modified vesicles successfully concentrated in affected joints and led to a marked reduction in RA symptoms. Overall, it’s clear that FA-GDEVs present a promising therapeutic option for those suffering from rheumatoid arthritis, bringing together safety, affordability, and effectiveness in one approach.
Our findings show that FA-GDEVs can help encourage a shift from harmful M1 macrophages to a healing M2 phenotype. This shift is significant because M2 macrophages play a role in tissue repair and reducing inflammation. We also investigated how these vesicles activate the PI3K-AKT pathway, a crucial cellular pathway involved in regulating immune response.
In our in vivo studies, we noted that these folate-modified vesicles successfully concentrated in affected joints and led to a marked reduction in RA symptoms. Overall, it’s clear that FA-GDEVs present a promising therapeutic option for those suffering from rheumatoid arthritis, bringing together safety, affordability, and effectiveness in one approach.
Read More
8
Folic acid aids RA treatment safety
We investigated the role of folic acid supplementation in helping elderly patients with rheumatoid arthritis (RA) who are treated with methotrexate (MTX). This study focused on understanding the incidence of adverse events (AEs) that lead patients to stop using MTX over time. We reviewed clinical data from 198 elderly RA patients who were receiving MTX in an outpatient rheumatology setting.
Over a period of 15 years, we found that the likelihood of patients stopping MTX due to AEs increased significantly, with rates reaching as high as 51.7%. Notably, we observed that higher doses of MTX (15 mg/wk or more) substantially raised the risk of withdrawal. In contrast, patients who took folic acid alongside their MTX therapy were less likely to discontinue treatment, suggesting a protective effect of folic acid against some of the adverse reactions.
Overall, our findings indicate that while MTX is a common treatment for RA, utilizing lower doses along with folic acid supplementation can help manage the risks associated with this medication. This approach could lead to improved long-term treatment outcomes for elderly patients with RA, allowing them to better navigate the challenges of their condition.
Over a period of 15 years, we found that the likelihood of patients stopping MTX due to AEs increased significantly, with rates reaching as high as 51.7%. Notably, we observed that higher doses of MTX (15 mg/wk or more) substantially raised the risk of withdrawal. In contrast, patients who took folic acid alongside their MTX therapy were less likely to discontinue treatment, suggesting a protective effect of folic acid against some of the adverse reactions.
Overall, our findings indicate that while MTX is a common treatment for RA, utilizing lower doses along with folic acid supplementation can help manage the risks associated with this medication. This approach could lead to improved long-term treatment outcomes for elderly patients with RA, allowing them to better navigate the challenges of their condition.
Read More
Most Useful Reviews
9
Hope for recovery
6 people found this helpful
An invaluable preparation! This wonderful drug has the potential to enhance my wife's health. After years of suffering from trigeminal neuralgia and relying on harmful medication, we can now consider alternatives thanks to regular folate intake. I've noticed an increase in energy, despite both being 79 years old, and I'm keen to order more.
Read More
9
Superior absorption seen
1 people found this helpful
The result was amazing! Solgar surpasses pharmacy vitamins! Regular folic acid was quickly excreted from my body. The doctor advised the Solgar version, which I had to order online. It was delivered ahead of time and at a fair price compared to local pharmacies. Solgar's folate is easily digestible and ideal for me—tests show my vitamin levels remain stable over months. I highly recommend it!
Read More
9
Successful conception
1 people found this helpful
My body never accepted regular Folic Acid, resulting in the loss of three babies. It upset my stomach too. Learning it was the culprit, I ordered L-Methyl folate, which isn't available in my country. After taking this mini pill for three months, I was able to conceive without complications.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 6 Researches
7.2
- All Researches
9
Folate's Role in Rheumatoid Arthritis
We explored the potential of folate-modified ginger-derived extracellular vesicles (FA-GDEVs) in treating rheumatoid arthritis (RA). This innovative approach aims to tackle the ongoing inflammation and joint damage that characterizes this autoimmune disorder. By using folate, which selectively targets specific receptors on inflammatory cells, we specifically directed these vesicles to M1 macrophages in inflamed joints.
Our findings show that FA-GDEVs can help encourage a shift from harmful M1 macrophages to a healing M2 phenotype. This shift is significant because M2 macrophages play a role in tissue repair and reducing inflammation. We also investigated how these vesicles activate the PI3K-AKT pathway, a crucial cellular pathway involved in regulating immune response.
In our in vivo studies, we noted that these folate-modified vesicles successfully concentrated in affected joints and led to a marked reduction in RA symptoms. Overall, it’s clear that FA-GDEVs present a promising therapeutic option for those suffering from rheumatoid arthritis, bringing together safety, affordability, and effectiveness in one approach.
Our findings show that FA-GDEVs can help encourage a shift from harmful M1 macrophages to a healing M2 phenotype. This shift is significant because M2 macrophages play a role in tissue repair and reducing inflammation. We also investigated how these vesicles activate the PI3K-AKT pathway, a crucial cellular pathway involved in regulating immune response.
In our in vivo studies, we noted that these folate-modified vesicles successfully concentrated in affected joints and led to a marked reduction in RA symptoms. Overall, it’s clear that FA-GDEVs present a promising therapeutic option for those suffering from rheumatoid arthritis, bringing together safety, affordability, and effectiveness in one approach.
Read More
8
We investigated the effects of a new treatment approach for rheumatoid arthritis (RA) that combines Methotrexate (MTX) with folate-liposomal delivery of RELA siRNA. This innovative method aims to target macrophages in the body, which play a critical role in inflammation, especially in autoimmune disorders.
In our study, we observed that using folate-liposomes to deliver both MTX and RELA siRNA leads to a notable reduction in synovial inflammation and improved mobility in a rat model of collagen-induced arthritis (CIA). This dual approach not only helps lower inflammatory markers in the body, like cytokines and C-reactive protein, but also appears to shift the behavior of macrophages from a pro-inflammatory state towards a more healing one.
Additionally, extensive tests showed that this therapy is stable and compatible with biological systems. It highlights the potential of using folate as a targeting agent in the treatment of RA, albeit we did not focus solely on folate’s effect on autoimmune disorders in isolation.
Overall, this research suggests a promising pathway for more effective RA treatments by tackling the root causes of inflammation and preventing further joint damage.
In our study, we observed that using folate-liposomes to deliver both MTX and RELA siRNA leads to a notable reduction in synovial inflammation and improved mobility in a rat model of collagen-induced arthritis (CIA). This dual approach not only helps lower inflammatory markers in the body, like cytokines and C-reactive protein, but also appears to shift the behavior of macrophages from a pro-inflammatory state towards a more healing one.
Additionally, extensive tests showed that this therapy is stable and compatible with biological systems. It highlights the potential of using folate as a targeting agent in the treatment of RA, albeit we did not focus solely on folate’s effect on autoimmune disorders in isolation.
Overall, this research suggests a promising pathway for more effective RA treatments by tackling the root causes of inflammation and preventing further joint damage.
Read More
8
Folic acid aids RA treatment safety
We investigated the role of folic acid supplementation in helping elderly patients with rheumatoid arthritis (RA) who are treated with methotrexate (MTX). This study focused on understanding the incidence of adverse events (AEs) that lead patients to stop using MTX over time. We reviewed clinical data from 198 elderly RA patients who were receiving MTX in an outpatient rheumatology setting.
Over a period of 15 years, we found that the likelihood of patients stopping MTX due to AEs increased significantly, with rates reaching as high as 51.7%. Notably, we observed that higher doses of MTX (15 mg/wk or more) substantially raised the risk of withdrawal. In contrast, patients who took folic acid alongside their MTX therapy were less likely to discontinue treatment, suggesting a protective effect of folic acid against some of the adverse reactions.
Overall, our findings indicate that while MTX is a common treatment for RA, utilizing lower doses along with folic acid supplementation can help manage the risks associated with this medication. This approach could lead to improved long-term treatment outcomes for elderly patients with RA, allowing them to better navigate the challenges of their condition.
Over a period of 15 years, we found that the likelihood of patients stopping MTX due to AEs increased significantly, with rates reaching as high as 51.7%. Notably, we observed that higher doses of MTX (15 mg/wk or more) substantially raised the risk of withdrawal. In contrast, patients who took folic acid alongside their MTX therapy were less likely to discontinue treatment, suggesting a protective effect of folic acid against some of the adverse reactions.
Overall, our findings indicate that while MTX is a common treatment for RA, utilizing lower doses along with folic acid supplementation can help manage the risks associated with this medication. This approach could lead to improved long-term treatment outcomes for elderly patients with RA, allowing them to better navigate the challenges of their condition.
Read More
7
We explored the relationship between folate treatment and vitamin B12 status in patients with rheumatoid arthritis (RA) who were being treated with methotrexate. This study involved 50 RA patients on methotrexate and folic acid, compared against 49 patients receiving other treatments. The aim was to see how well these treatments supported vitamin B12 levels and affected homocysteine, a marker associated with cardiovascular risk.
Our findings revealed that while plasma vitamin B12 levels remained comparable between the two groups, those treated with methotrexate and folic acid exhibited higher plasma homocysteine levels. Elevated homocysteine can signal a potential vitamin B12 deficiency, which is a concern for those on methotrexate due to the medication's known side effects. This suggests that while folate is being administered, some patients might still be at risk of complications related to vitamin B12 levels.
In conclusion, the treatment regimen combining methotrexate with folic acid may not be enough to fully mitigate the risks associated with vitamin B12 deficiency in RA patients. Hence, additional research is essential to understand these interactions better and to assess the clinical signs that could arise from low B12 levels and hyperhomocysteinemia among this group.
Our findings revealed that while plasma vitamin B12 levels remained comparable between the two groups, those treated with methotrexate and folic acid exhibited higher plasma homocysteine levels. Elevated homocysteine can signal a potential vitamin B12 deficiency, which is a concern for those on methotrexate due to the medication's known side effects. This suggests that while folate is being administered, some patients might still be at risk of complications related to vitamin B12 levels.
In conclusion, the treatment regimen combining methotrexate with folic acid may not be enough to fully mitigate the risks associated with vitamin B12 deficiency in RA patients. Hence, additional research is essential to understand these interactions better and to assess the clinical signs that could arise from low B12 levels and hyperhomocysteinemia among this group.
Read More
7
We aimed to understand how folate receptor alpha autoantibodies (FRAAs) relate to symptoms in children diagnosed with Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS). We analyzed serum samples from 47 children, aged 6 to 18, who carried these diagnoses.
Our results showed that a significant number of these children—about 63.8%—had binding or blocking FRAAs. Additionally, certain symptoms, like severe tics, linked with higher FRAA binding titers. Notably, we observed that kids with autism spectrum disorder (ASD) had lower binding titers of FRAAs.
A remarkable case highlighted how treatment with leucovorin, a form of folate, resulted in symptom improvements in a child with PANS/PANDAS who tested positive for FRAAs. These findings suggest that abnormalities in folate metabolism could play a role in the symptomatology of PANS/PANDAS, presenting the potential for folate-based therapies to be a viable treatment option.
Overall, this study sheds light on the connection between folate-related factors and pediatric neuropsychiatric disorders, calling for further research into leucovorin as a targeted treatment.
Our results showed that a significant number of these children—about 63.8%—had binding or blocking FRAAs. Additionally, certain symptoms, like severe tics, linked with higher FRAA binding titers. Notably, we observed that kids with autism spectrum disorder (ASD) had lower binding titers of FRAAs.
A remarkable case highlighted how treatment with leucovorin, a form of folate, resulted in symptom improvements in a child with PANS/PANDAS who tested positive for FRAAs. These findings suggest that abnormalities in folate metabolism could play a role in the symptomatology of PANS/PANDAS, presenting the potential for folate-based therapies to be a viable treatment option.
Overall, this study sheds light on the connection between folate-related factors and pediatric neuropsychiatric disorders, calling for further research into leucovorin as a targeted treatment.
Read More
User Reviews
USERS' SCORE
Good
Based on 14 Reviews
8.2
- All Reviews
- Positive Reviews
- Negative Reviews
9
Hope for recovery
6 people found this helpful
An invaluable preparation! This wonderful drug has the potential to enhance my wife's health. After years of suffering from trigeminal neuralgia and relying on harmful medication, we can now consider alternatives thanks to regular folate intake. I've noticed an increase in energy, despite both being 79 years old, and I'm keen to order more.
Read More
9
Superior absorption seen
1 people found this helpful
The result was amazing! Solgar surpasses pharmacy vitamins! Regular folic acid was quickly excreted from my body. The doctor advised the Solgar version, which I had to order online. It was delivered ahead of time and at a fair price compared to local pharmacies. Solgar's folate is easily digestible and ideal for me—tests show my vitamin levels remain stable over months. I highly recommend it!
Read More
9
Successful conception
1 people found this helpful
My body never accepted regular Folic Acid, resulting in the loss of three babies. It upset my stomach too. Learning it was the culprit, I ordered L-Methyl folate, which isn't available in my country. After taking this mini pill for three months, I was able to conceive without complications.
Read More
9
Cycle recovery
1 people found this helpful
I have a violation of the folate cycle, so my doctor prescribed folate. These tablets are perfect for me, and I take one twice daily. Following childbirth, my cycle quickly became regular and painless. This supplement is crucial for women like me with folate cycle issues.
Read More
9
Great product!
1 people found this helpful
Good folic acid for pregnant women and those planning to conceive, particularly with folate deficiency. I've ordered this multiple times and can confidently say it’s the best!
Read More
Frequently Asked Questions
7.5
Cycle improvement noted
1 people found this helpful
The female cycle has improved as I drink these vitamins daily. I take one tablet each morning after meals; occasionally, I take two. So far, there have been no side effects or allergic reactions. The drug is well tolerated and has a neutral taste. The effects take time, but I began noticing improvements after about a week, especially as I feel stressed about work. I believe taking folic acid has helped address these serious problems.
9
Homocysteine reduction achieved
4 people found this helpful
I ordered this to reduce homocysteine levels. The goods arrived rapidly, well before the expected three weeks. My homocysteine decreased from 11.59 to 4.37 within a month. Previous supplements did not help due to my mutation. I’ll definitely order more.
9
Successful conception
1 people found this helpful
My body never accepted regular Folic Acid, resulting in the loss of three babies. It upset my stomach too. Learning it was the culprit, I ordered L-Methyl folate, which isn't available in my country. After taking this mini pill for three months, I was able to conceive without complications.
2
No difference noted
1 people found this helpful
Not sure I have taken this for over a week and I can't say I feel any difference at all. Perhaps one needs to be deficient in folate to benefit from it. Excellent service from iHerb and competitive pricing.
9
Hope for recovery
6 people found this helpful
An invaluable preparation! This wonderful drug has the potential to enhance my wife's health. After years of suffering from trigeminal neuralgia and relying on harmful medication, we can now consider alternatives thanks to regular folate intake. I've noticed an increase in energy, despite both being 79 years old, and I'm keen to order more.
7.5
Correct folate form
39 people found this helpful
This is the correct form of folate! I had unknowingly taken folic acid without seeing results. Tests showed my homocysteine level was rising due to MTHFR gene polymorphism. After switching to methofolin, I noticed a significant improvement, confirmed by subsequent blood tests showing decreased homocysteine levels.
9
Cycle recovery
1 people found this helpful
I have a violation of the folate cycle, so my doctor prescribed folate. These tablets are perfect for me, and I take one twice daily. Following childbirth, my cycle quickly became regular and painless. This supplement is crucial for women like me with folate cycle issues.
9
Folate's Role in Rheumatoid Arthritis
We explored the potential of folate-modified ginger-derived extracellular vesicles (FA-GDEVs) in treating rheumatoid arthritis (RA). This innovative approach aims to tackle the ongoing inflammation and joint damage that characterizes this autoimmune disorder. By using folate, which selectively targets specific receptors on inflammatory cells, we specifically directed these vesicles to M1 macrophages in inflamed joints.
Our findings show that FA-GDEVs can help encourage a shift from harmful M1 macrophages to a healing M2 phenotype. This shift is significant because M2 macrophages play a role in tissue repair and reducing inflammation. We also investigated how these vesicles activate the PI3K-AKT pathway, a crucial cellular pathway involved in regulating immune response.
In our in vivo studies, we noted that these folate-modified vesicles successfully concentrated in affected joints and led to a marked reduction in RA symptoms. Overall, it’s clear that FA-GDEVs present a promising therapeutic option for those suffering from rheumatoid arthritis, bringing together safety, affordability, and effectiveness in one approach.
Our findings show that FA-GDEVs can help encourage a shift from harmful M1 macrophages to a healing M2 phenotype. This shift is significant because M2 macrophages play a role in tissue repair and reducing inflammation. We also investigated how these vesicles activate the PI3K-AKT pathway, a crucial cellular pathway involved in regulating immune response.
In our in vivo studies, we noted that these folate-modified vesicles successfully concentrated in affected joints and led to a marked reduction in RA symptoms. Overall, it’s clear that FA-GDEVs present a promising therapeutic option for those suffering from rheumatoid arthritis, bringing together safety, affordability, and effectiveness in one approach.
8
We investigated the effects of a new treatment approach for rheumatoid arthritis (RA) that combines Methotrexate (MTX) with folate-liposomal delivery of RELA siRNA. This innovative method aims to target macrophages in the body, which play a critical role in inflammation, especially in autoimmune disorders.
In our study, we observed that using folate-liposomes to deliver both MTX and RELA siRNA leads to a notable reduction in synovial inflammation and improved mobility in a rat model of collagen-induced arthritis (CIA). This dual approach not only helps lower inflammatory markers in the body, like cytokines and C-reactive protein, but also appears to shift the behavior of macrophages from a pro-inflammatory state towards a more healing one.
Additionally, extensive tests showed that this therapy is stable and compatible with biological systems. It highlights the potential of using folate as a targeting agent in the treatment of RA, albeit we did not focus solely on folate’s effect on autoimmune disorders in isolation.
Overall, this research suggests a promising pathway for more effective RA treatments by tackling the root causes of inflammation and preventing further joint damage.
In our study, we observed that using folate-liposomes to deliver both MTX and RELA siRNA leads to a notable reduction in synovial inflammation and improved mobility in a rat model of collagen-induced arthritis (CIA). This dual approach not only helps lower inflammatory markers in the body, like cytokines and C-reactive protein, but also appears to shift the behavior of macrophages from a pro-inflammatory state towards a more healing one.
Additionally, extensive tests showed that this therapy is stable and compatible with biological systems. It highlights the potential of using folate as a targeting agent in the treatment of RA, albeit we did not focus solely on folate’s effect on autoimmune disorders in isolation.
Overall, this research suggests a promising pathway for more effective RA treatments by tackling the root causes of inflammation and preventing further joint damage.
We looked into how folate, an essential nutrient in our diet, might influence the health of individuals with systemic lupus erythematosus (SLE), an autoimmune disorder that carries a heightened risk of cardiovascular disease. Our investigation involved a case-control study with 394 Mexican-mestizo women, where we sought to find connections between certain genetic variants related to folate metabolism and heart health in SLE patients.
Surprisingly, our results showed that the overall levels of folate and homocysteine—both important in the context of heart health—didn't differ significantly between those with SLE and healthy controls. However, we did observe that the genetic variant c.+677 C>T (known as the CC genotype) appeared to offer some protective benefit against cardiovascular issues, suggesting that people with this genetic makeup might have a lower risk of heart disease.
On the flip side, two specific haplotypes from the c.+677 and c.+1298 genetic variants were linked to an increased risk for SLE itself. This suggests that while folate's role in the body is vital and its genetic connections intricate, treating SLE patients with folate alone may not yield significant improvements in their condition based on these findings.
Overall, while we documented interesting associations between genetic variants and disease risk in SLE, we didn't find strong evidence supporting direct benefits of folate treatment in mitigating the disorder's impact.
Surprisingly, our results showed that the overall levels of folate and homocysteine—both important in the context of heart health—didn't differ significantly between those with SLE and healthy controls. However, we did observe that the genetic variant c.+677 C>T (known as the CC genotype) appeared to offer some protective benefit against cardiovascular issues, suggesting that people with this genetic makeup might have a lower risk of heart disease.
On the flip side, two specific haplotypes from the c.+677 and c.+1298 genetic variants were linked to an increased risk for SLE itself. This suggests that while folate's role in the body is vital and its genetic connections intricate, treating SLE patients with folate alone may not yield significant improvements in their condition based on these findings.
Overall, while we documented interesting associations between genetic variants and disease risk in SLE, we didn't find strong evidence supporting direct benefits of folate treatment in mitigating the disorder's impact.
8
Folic acid aids RA treatment safety
We investigated the role of folic acid supplementation in helping elderly patients with rheumatoid arthritis (RA) who are treated with methotrexate (MTX). This study focused on understanding the incidence of adverse events (AEs) that lead patients to stop using MTX over time. We reviewed clinical data from 198 elderly RA patients who were receiving MTX in an outpatient rheumatology setting.
Over a period of 15 years, we found that the likelihood of patients stopping MTX due to AEs increased significantly, with rates reaching as high as 51.7%. Notably, we observed that higher doses of MTX (15 mg/wk or more) substantially raised the risk of withdrawal. In contrast, patients who took folic acid alongside their MTX therapy were less likely to discontinue treatment, suggesting a protective effect of folic acid against some of the adverse reactions.
Overall, our findings indicate that while MTX is a common treatment for RA, utilizing lower doses along with folic acid supplementation can help manage the risks associated with this medication. This approach could lead to improved long-term treatment outcomes for elderly patients with RA, allowing them to better navigate the challenges of their condition.
Over a period of 15 years, we found that the likelihood of patients stopping MTX due to AEs increased significantly, with rates reaching as high as 51.7%. Notably, we observed that higher doses of MTX (15 mg/wk or more) substantially raised the risk of withdrawal. In contrast, patients who took folic acid alongside their MTX therapy were less likely to discontinue treatment, suggesting a protective effect of folic acid against some of the adverse reactions.
Overall, our findings indicate that while MTX is a common treatment for RA, utilizing lower doses along with folic acid supplementation can help manage the risks associated with this medication. This approach could lead to improved long-term treatment outcomes for elderly patients with RA, allowing them to better navigate the challenges of their condition.
References
- Han R, Zhou D, Ji N, Yin Z, Wang J, et al. Folic acid-modified ginger-derived extracellular vesicles for targeted treatment of rheumatoid arthritis by remodeling immune microenvironment via the PI3K-AKT pathway. J Nanobiotechnology. 2025;23:41. doi:10.1186/s12951-025-03096-5
- Nasra S, Bhatia D, Kumar A. Targeted Macrophage Re-Programming: Synergistic Therapy With Methotrexate and RELA siRNA Folate-Liposome in RAW264.7 Cells and Arthritic Rats. Adv Healthc Mater. 2024;13:e2400679. doi:10.1002/adhm.202400679
- Pesqueda-Cendejas K, Parra-Rojas I, Campos-López B, Mora-García PE, Ruiz-Ballesteros AI, et al. Association of c.+677 C>T (rs1801133) and c.+1298 A>C (rs1801131) genetic variants with cardiometabolic and disease risk in systemic lupus erythematosus patients: A cross-sectional study. Lupus. 2024;33:918. doi:10.1177/09612033241257158
- Avalos-Salgado FA, Gonzalez-Lopez L, Gonzalez-Vazquez S, Ponce-Guarneros JM, Santiago-Garcia AP, et al. Risk Factors Associated with Adverse Events Leading to Methotrexate Withdrawal in Elderly Rheumatoid Arthritis Patients: A Retrospective Cohort Study. J Clin Med. 2024;13. doi:10.3390/jcm13071863
- Patel AV, Morgan SL, Green R, Danila MI, Merriman TR, et al. Vitamin B12 status and hyperhomocysteinemia in patients with Rheumatoid arthritis treated with methotrexate and folic acid. Am J Med Sci. 2024;368:33. doi:10.1016/j.amjms.2024.03.020
- Wells L, O'Hara N, Frye RE, Hullavard N, Smith E. Folate Receptor Alpha Autoantibodies in the Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) and Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) Population. J Pers Med. 2024;14. doi:10.3390/jpm14020166
